vTv Therapeutics
VTVT
27 hedge funds and large institutions have $3.38M invested in vTv Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
23% more capital invested
Capital invested by funds: $2.75M → $3.38M (+$634K)
17% more funds holding
Funds holding: 23 → 27 (+4)
0.03% less ownership
Funds ownership: 0.14% → 0.11% (-0.03%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$26.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$14.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.5K |
| 4 |
VF
Virtu Financial
New York
|
+$5.31K |
| 5 |
FWM
Focused Wealth Management
Newburgh,
New York
|
+$4.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$75.4K |
| 2 |
State Street
Boston,
Massachusetts
|
-$70.3K |
| 3 |
Millennium Management
New York
|
-$60.4K |
| 4 |
EGM
Engineers Gate Manager
New York
|
-$12K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.21K |
VTVT Hedge Fund Activity: Q3 2022 in Review
27 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2022, worth a combined $3.38M — up 23% from $2.75M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VTVT positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $26.6K. The largest seller was Geode Capital Management, cutting an estimated $75.4K.
- 27 institutional investors held vTv Therapeutics (VTVT) as of Q3 2022, up from 23 in Q2 2022.
- Funds reported $3.38M of vTv Therapeutics stock for Q3 2022, up 23% quarter-over-quarter.
- 5 funds opened new vTv Therapeutics positions in Q3 2022 and 1 closed out, a net change of +4 holders.
- The largest vTv Therapeutics buyer in Q3 2022 was Bridgeway Capital Management, an estimated $26.6K added.
- The largest vTv Therapeutics seller in Q3 2022 was Geode Capital Management, an estimated $75.4K sold.
Based on aggregated 13F filings for Q3 2022.